Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostate Cancer and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLK4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLK4 Recombinant Protein (Active/Pro-form) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed (Native Glycosylation). |
View KLK4 Products |
| Gene Delivery | KLK4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KLK4 Products |
| Benchmark Ab | Anti-KLK4 Reference Antibody Recombinant positive control for assay development. |
View KLK4 Products |
| Validator | KLK4 siRNA Set For knockdown verification and specificity checks. |
View KLK4 Products |
| Related Target A | KLK3 (PSA) Critical family member for off-target selectivity screening. |
View KLK3 Products |
| Related Target B | KLK2 Prostate-associated peptidase, synergistic pathway validation. |
View KLK2 Products |
| Related Target C | KLK11 Compensatory pathway member; combination therapy candidate. |
View KLK11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening (vs KLK1-15) | Sequence Verified, High Purity (>95%) Homolog panel proteins (KLK2/3/4/11) available for strict selectivity assays. |
| Protease Conformational Integrity | HEK293 Expressed (Native Glycosylation) to ensure proper structural folding. |
| Lack of Reliable Controls | Recombinant positive control antibodies included. |
| False Positives in Cell Assays | Sequence-verified siRNA included for precise specificity checks. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno KLK4 ortholog proteins with native glycosylation (HEK293 expressed). |
Live KLK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLK4 therapeutics is intensifying, particularly within the urological oncology space. Overexpressed in prostate cancer, KLK4 (Kallikrein-related peptidase 4) is shifting from being purely a biomarker to a direct therapeutic target. As first-generation small molecule inhibitors enter early evaluation, the next wave of R&D is targeting Antibody-Drug Conjugates (ADCs) to exploit its tumor-specific expression profile. Combination therapies with androgen receptor (AR) inhibitors are also being explored to address castration-resistant prostate cancer (CRPC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Early-stage Biotech / Academics | Prostate Cancer, Breast Cancer | Selectivity Assay (Need High-Purity KLK4 vs KLK3) |
| ADC / mAbs | Emerging Oncology Pipelines | Solid Tumors | Internalization Assay (Need High-Purity HEK293 Antigen) |
| Peptide Inhibitors | Specialty Pharma | Tumor Microenvironment | Affinity Validation (Need Endotoxin Controlled Proteins) |
| Biomarker Assay | Diagnostic Companies | Prostate Cancer Screening | High-purity Antigen Standards (Sequence-verified KLK4 mutants) |
Molecular Differentiation & Assay Strategy
Selectivity (Core Challenge)
KLK family includes 15 highly homologous members (e.g., KLK2, KLK3). New drugs must achieve >100-fold selectivity to avoid off-target effects.
- Assay Recommendation: High-throughput cross-reactivity panel (SPR/BLI) covering KLK1-15.
Enzymatic Activity vs Binding
KLK4 is secreted as a pro-form (pro-KLK4) and requires activation. Inhibitors may have differential affinity for zymogen vs active form.
- Assay Recommendation: FRET-based enzymatic activity assay; SPR/BLI for binding affinity using both pro-form and active-form proteins.
Cross-species Epitopes
Preclinical studies require orthologs from mouse, rat, and cynomolgus monkey (human-mouse KLK4 homology ~60%).
- Assay Recommendation: Multi-species affinity binding assay (SPR) using Human, Cyno, Mouse, Rat orthologs.
Substrate Specificity
KLK4 and KLK3 have overlapping substrate profiles but distinct pathological cleavage sites.
- Assay Recommendation: Cleavage assays using pathological substrates (e.g., Fibronectin, Laminin) rather than generic substrates.
TarMart Solution Matching Strategy
- High Purity (>95%) & HEK293 Expression (Native Glycosylation): Serine protease conformation is sensitive to glycosylation. E. coli-expressed proteins often lack activity or fold incorrectly. HEK293-expressed KLK4 ensures native glycosylation, preserving enzymatic activity and epitope authenticity—essential for screening high-specificity antibodies and small molecules.
- Family Target Matrix: Provides highly purified KLK2, KLK3, KLK11 family member proteins, directly meeting "Subfamily counter screening" needs.
- Active-site Mutants: Catalytically inactive mutants (e.g., S214A) available as negative controls for distinguishing catalytic from allosteric inhibition.
Related Target Recommendations
Must-Screen Panel (Off-target)
- KLK3 (PSA): Co-expressed with KLK4 in prostate tissue; gold standard for selectivity screening.
- KLK2: Highest homology to KLK4; primary off-target risk.
Synergistic Mechanism Targets (Combination Therapy)
- KLK11: Compensatory upregulation in some breast cancers; consider dual-target inhibition.
- AR (Androgen Receptor): KLK4 expression is regulated by AR signaling; combined KLK4+AR pathway research tools recommended.
Diagnostic Companion Targets
- KLK4 vs KLK3 Dual Marker Assay: For distinguishing malignant from benign prostate lesions; recommend simultaneous procurement of KLK3 and KLK4 protein standards for diagnostic standard curve construction.